{"text": "For respective comparisons of ALLO and AUTO transplants in the GLN and GLY hematologic groups and AUTO in the solid tumor groups, there were no significant differences in hospital stay, duration of stay after BMT, TPN days, neutrophil recovery >500/mm3, incidence of positive blood cultures, sepsis, mucositis, and diarrhea.", "user_data": {"pmid": "10338217"}}
{"text": "Acute graft us host disease occurred in 1 of 10 hematologic patients receiving GLN and in 3 of 8 patients receiving GLY placebo (p > .05).", "user_data": {"pmid": "10338217"}}
{"text": "Possible reduction in need for TPN and a suggestion of improved long-term survival were associated with GLN.", "user_data": {"pmid": "10338217"}}
{"text": "The neutrophil nadir was similar with and without priming (mean +/- SD, 490 +/- 310/microL v 550 +/- 350/microL, respectively; P =.2); however, on day 16 the mean neutrophil count was higher (mean +/- SD, 1030 +/- 580/microL v 690 +/- 370/microL, P =.004), and the proportion of patients with a neutrophil count less than 500/microL was lower after priming than before (six of 35 or 17.1% v 12 of 34 or 35.3%, respectively; P =.04).", "user_data": {"pmid": "10550137"}}
{"text": "Episodes of fever and neutropenia were not observed.", "user_data": {"pmid": "10550137"}}
{"text": "Hematologic toxicity was similar.", "user_data": {"pmid": "10963640"}}
{"text": "Nausea/vomiting and stomatitis were significantly less frequent in arm A as was left ventricular ejection fraction decrease in arm C (A = six patients, B = five patients, and C = one patient).", "user_data": {"pmid": "10963640"}}
{"text": "The ORR was better with the longer regimens (arm A, 56.9%; B, 64%; and C, 47.6%; P: =.06) and was 41% after second-line FEC 100.", "user_data": {"pmid": "10963640"}}
{"text": "After a median follow-up of 41 months, the response duration and time to progression (TTP) were significantly better with arm B, the longer regimen (P: =.012 and P: < 10(-3), respectively).", "user_data": {"pmid": "10963640"}}
{"text": "The median survival times for arms A, B, and C were similar (17.9, 18.9, and 16.3 months, respectively; P: =.49).", "user_data": {"pmid": "10963640"}}
{"text": "The best prognostic factor for one-year survival was the response rate (P < 0.0001).", "user_data": {"pmid": "10997806"}}
{"text": "With a relative dose intensity of paclitaxel 0.94 in both groups, neurotoxicity (P = 0.025) and leucopenia (P = 0.038) were more pronounced in group B patients.", "user_data": {"pmid": "10997806"}}
{"text": "No toxic death was observed.", "user_data": {"pmid": "10997806"}}
{"text": "There was more hematotoxicity, peripheral neuropathy, and arthralgia/myalgia on the paclitaxel/cisplatin arm, whereas the high-dose cisplatin arm produced more ototoxicity, nausea, vomiting, and nephrotoxicity.", "user_data": {"pmid": "11013280"}}
{"text": "Quality of life (QOL) was similar overall between the two arms.", "user_data": {"pmid": "11013280"}}
{"text": "One hundred twenty eligible patients were randomized.", "user_data": {"pmid": "11013281"}}
{"text": "A 57% response rate was seen in the combined-modality arm (95% confidence interval [CI], 43% to 69%), and a 22% response rate was seen in the teniposide-alone arm (95% CI, 12% to 34%) (P<.001).", "user_data": {"pmid": "11013281"}}
{"text": "Time to progression in the brain was longer in the combined-modality group (P=.005).", "user_data": {"pmid": "11013281"}}
{"text": "Clinical response and response outside the brain were not different.", "user_data": {"pmid": "11013281"}}
{"text": "Overall survival in both groups was not different (P=.087).", "user_data": {"pmid": "11013281"}}
{"text": "Cardiovascular event rates were not statistically significantly different between women assigned to receive tamoxifen and those assigned to receive placebo, independent of pre-existing CHD.", "user_data": {"pmid": "11136837"}}
{"text": "Among women without CHD (6074 on tamoxifen versus 6072 on placebo), risk ratios (95% confidence intervals [CIs]) for tamoxifen users were 1.75 (0.44 to 8.13) for fatal myocardial infarction, 1.11 (0.55 to 2.28) for nonfatal myocardial infarction, 0.69 (0.29 to 1.57) for unstable angina, and 0.83 (0.32 to 2.10) for severe angina.", "user_data": {"pmid": "11136837"}}
{"text": "In women with CHD (516 on tamoxifen versus 532 on placebo), risk ratios (95% CIs) for tamoxifen users were 0.00 (0 to 1.58) for fatal myocardial infarction, 1.25 (0.32 to 5.18) for nonfatal myocardial infarction, 2.26 (0.87 to 6.55) for unstable angina, and 1.39 (0.23 to 9.47) for severe angina.", "user_data": {"pmid": "11136837"}}
{"text": "There was no evidence that the lack of association between tamoxifen and cardiovascular events was related to an early increase in risk that may have been offset by a late decrease in risk.", "user_data": {"pmid": "11136837"}}
{"text": "They comprised the intent-to-treat population.", "user_data": {"pmid": "11454878"}}
{"text": "The overall progression-free survival rates were similar between the two arms (P =.095).", "user_data": {"pmid": "11454878"}}
{"text": "The platinum-refractory subgroup demonstrated a nonstatistically significant survival trend in favor of topotecan (P =.455).", "user_data": {"pmid": "11454878"}}
{"text": "Severe hematologic toxicity was more common with topotecan and was more likely to be associated with dosage modification, or growth factor or blood product utilization.", "user_data": {"pmid": "11454878"}}
{"text": "Median age was 54 years in both treatment groups.", "user_data": {"pmid": "11815957"}}
{"text": "All relevant prognostic factors were balanced, with the exception that there were significantly more progesterone receptor positive patients in the doxorubicin-treated group.", "user_data": {"pmid": "11815957"}}
{"text": "The overall response rate was 26% in both treatment groups.", "user_data": {"pmid": "11815957"}}
{"text": "Clinical toxicities, commonly associated with doxorubicin, appeared less common with TLC D-99, although the difference was not statistically significant.", "user_data": {"pmid": "11815957"}}
{"text": "Standard histopathological analysis revealed no lymph node involvement (pN0) in 61 patients, pN1 disease in 13 patients and pN2 disease in 20 patients without significant differences between LA and LS with respect to T-stage, N-stage or age and sex of the patients.", "user_data": {"pmid": "11888774"}}
{"text": "Similar to the entire group of patients also in the subset of patients with nodal micrometastases the type of lymphadenectomy did not significantly influence the long-term survival (P=0.27 and P=0.39, respectively).", "user_data": {"pmid": "11888774"}}
{"text": "In contrast, in patients with a negative immunohistochemical analysis systematic lymphadenectomy resulted in an improved overall survival (P=0.044).", "user_data": {"pmid": "11888774"}}
{"text": "Serum-free estradiol and estrone levels decreased moderately in the experimental group.", "user_data": {"pmid": "11920488"}}
{"text": "In addition, women who were taking soy had their mean follicular phase increase by 1.46 days compared with a mean increase of 0.14 days for women who were taking the placebo (P = 0.08).", "user_data": {"pmid": "11920488"}}
{"text": "Patients in group C had a significantly reduced need for propofol (P < 0.04) and sevoflurane (P < 0.01) and a reduced early need for ketobemidone (P < 0.04).", "user_data": {"pmid": "11981150"}}
{"text": "The number needed to treat was 3.3 (95% confidence interval, 1.8, 16.9).", "user_data": {"pmid": "11981150"}}
{"text": "Intraoperative blood pressure, postoperative heart rate, and postoperative blood pressure were all significantly lower in group C compared with group P, but were not considered to be of clinical importance.", "user_data": {"pmid": "11981150"}}
{"text": "No negative side effects were recorded.", "user_data": {"pmid": "11981150"}}
{"text": "Gastrointestinal side effects and hand-foot syndrome were more common with combination therapy, whereas myalgia, arthralgia, and neutropenic fever/sepsis were more common with single-agent docetaxel.", "user_data": {"pmid": "12065558"}}
{"text": "Circulating tumour cells were detected and monitored throughout treatment periods.", "user_data": {"pmid": "12116339"}}
{"text": "An initial rise in circulating cells after the first cycle was followed by a fall in both treatment arms to baseline levels set by normal controls.", "user_data": {"pmid": "12116339"}}
{"text": "At week 6, hot flashes were reduced by 86% on average in the whole group of patients, without significant differences between the two progestins.", "user_data": {"pmid": "12123333"}}
{"text": "Responders were followed to assess maintenance of response (without further treatment), which was significantly better with i.m. MPA: in this group, 89% of responders still showed a benefit at week 24, compared with 45% in the megestrol group (P = 0.03).", "user_data": {"pmid": "12123333"}}
{"text": "Analyses of self-reported daily activity levels revealed a diffusion of treatment effect.", "user_data": {"pmid": "12406050"}}
{"text": "Analyses of self-reported disease symptoms and treatment side effects did not reveal clinically meaningful differences between the two groups.", "user_data": {"pmid": "12406050"}}
{"text": "When comparing all four arms, there was a progression-free difference among WP RT + NCHT, PO RT + NCHT, WP RT + AHT, and PO RT + AHT (60% v 44% v 49% v 50%, respectively; P =.008).", "user_data": {"pmid": "12743142"}}
{"text": "No survival advantage has yet been seen.", "user_data": {"pmid": "12743142"}}
{"text": "Arzoxifene was well tolerated.", "user_data": {"pmid": "12954577"}}
{"text": "There were no study drug-related deaths.", "user_data": {"pmid": "12954577"}}
{"text": "A total of 226 patients were evaluable for response.", "user_data": {"pmid": "14679127"}}
{"text": "Demographic characteristics were similar in both treatment groups, as were results of the EORTC QOL-30 questionnaire.", "user_data": {"pmid": "14679127"}}
{"text": "Subgroup results were consistent.", "user_data": {"pmid": "14998846"}}
{"text": "Overall risk of cardiotoxicity was significantly higher with doxorubicin than PLD (HR=3.16; 95%CI 1.58-6.31; P<0.001).", "user_data": {"pmid": "14998846"}}
{"text": "Chemotherapy was given before surgery in 3% of patients whilst 97% received adjuvant chemotherapy.", "user_data": {"pmid": "15200998"}}
{"text": "Baseline characteristics were: median age 61 years, 69% male, 48% squamous cell, 93% WHO PS 0-1, 27% stage I, 38% stage II, and 34% stage III.", "user_data": {"pmid": "15200998"}}
{"text": "Complete resection was achieved in approximately 95% of patients.", "user_data": {"pmid": "15200998"}}
{"text": "30% had grade 3/4 toxicity, mainly haematological, nausea/vomiting and neutropenic fever, and six patients were reported as having a treatment-related death.", "user_data": {"pmid": "15200998"}}
{"text": "198 (52%) of patients have died, but there is currently no evidence of a benefit in overall survival to the C group: HR 1.02 (95% CI 0.77-1.35), P = 0.90).", "user_data": {"pmid": "15200998"}}
{"text": "No major complication was noted.", "user_data": {"pmid": "15217131"}}
{"text": "The volume in the pelvic drain 20 min post-operatively and after 48 hours failed to reach statistical significance between the two groups (P= 0.10 and P= 0.165).", "user_data": {"pmid": "15713151"}}
{"text": "There were no differences in uterine artery Doppler resistance indices at five days (P= 0.54), six weeks (P= 0.47), three months (P= 0.49) and at six months (P= 0.18).", "user_data": {"pmid": "15713151"}}
{"text": "Day two serum FSH concentrations after surgery were unchanged (P= 0.45), compared with baseline values.", "user_data": {"pmid": "15713151"}}
{"text": "The SRE rate ratio at 1 year (excluding HCM and adjusted for prior fracture) was 0.61 (permutation test; P = .027), indicating that zoledronic acid reduced the rate of SRE by 39% compared with placebo.", "user_data": {"pmid": "15738536"}}
{"text": "Zoledronic acid significantly delayed time-to-first SRE (median not reached v 364 days; Cox regression; P = .007) and reduced the risk of SREs by 41% in multiple event analysis (risk ratio = 0.59; P = .019) compared with placebo.", "user_data": {"pmid": "15738536"}}
{"text": "Zoledronic acid was well tolerated with a safety profile similar to placebo.", "user_data": {"pmid": "15738536"}}
{"text": "No patient treated with zoledronic acid had grade 3 or 4 serum creatinine increase.", "user_data": {"pmid": "15738536"}}
{"text": "Compliance was >90% in all patients.", "user_data": {"pmid": "15774238"}}
{"text": "In the intervention group, plasma levels of vitamin E, selenium and coenzyme Q10 increased significantly over the 21 weeks study period.", "user_data": {"pmid": "15774238"}}
{"text": "No significant differences in serum levels of PSA, testosterone, dihydrotestosterone, luteinizing hormone or sex hormone binding globulin (p>0.2) were observed between the intervention and control group.", "user_data": {"pmid": "15774238"}}
{"text": "Of 141 patients enrolled, 83% were randomly assigned after chemotherapy to qdRT (n = 59) or HART (n = 60).", "user_data": {"pmid": "15837967"}}
{"text": "Any subsequent trials of the HART regimen must address the issues that led to early closure, including slow accrual, logistics of HART, mucosal toxicity, and the fact that concurrent chemoradiotherapy now seems more effective than sequential treatment.", "user_data": {"pmid": "15837967"}}
{"text": "Prolonged survival was observed with both drugs, with 10-20% of patients still alive > 5 years after randomization.", "user_data": {"pmid": "15937908"}}
{"text": "Fulvestrant continued to be well tolerated, and was associated with a significantly lower incidence of joint disorders compared with anastrozole (P = 0.0234).", "user_data": {"pmid": "15937908"}}
{"text": "In those with prostate cancer these changes were 23.8% and -37.2%, respectively.", "user_data": {"pmid": "16600723"}}
{"text": "The 15-year actuarial locoregional recurrence rate was 7% for the q.d. arm and 12% for the b.i.d. arm (p=0.36).", "user_data": {"pmid": "16750325"}}
{"text": "The rates of severe acute toxicity were similar (4% for q.d. vs. 5% for b.i.d.), but moist desquamation developed in 42% of patients in the b.i.d. arm compared with 28% of the patients in the q.d. arm (p=0.16).", "user_data": {"pmid": "16750325"}}
{"text": "Multivariate analysis showed local control increased with age (P=0.0003).", "user_data": {"pmid": "17126434"}}
{"text": "There was no evidence that the relative effect of a boost on local control depends on age (P=0.97) However in younger patients the 5-year local failure was higher, therefore the absolute reduction was greater.", "user_data": {"pmid": "17126434"}}
{"text": "If the threshold-age for boost treatment were set at 40 years, 8.4% of the study population would receive a boost, resulting in a 5-year local failure of 6.1% in the study population.", "user_data": {"pmid": "17126434"}}
{"text": "Changing the threshold-age to 60 years, 67% of the study population would receive a boost and the 5-year local failure would be reduced to 4.4%.", "user_data": {"pmid": "17126434"}}
{"text": "In retrospectively defined subgroups, significant improvement in PFS in favor of dofequidar was observed in patients who were premenopausal, had no prior therapy, and were stage IV at diagnosis with an intact primary tumor.", "user_data": {"pmid": "17179098"}}
{"text": "Except for neutropenia and leukopenia, there was no statistically significant excess of grade 3/4 adverse events compared with CAF.", "user_data": {"pmid": "17179098"}}
{"text": "Treatment with dofequidar did not affect the plasma concentration of doxorubicin.", "user_data": {"pmid": "17179098"}}
{"text": "The tumor size (P = 0.07), TNM stage (P = 0.39) and cumulative breast cancer mortality rate (P = 0.72) were not significantly different between the 2 groups.", "user_data": {"pmid": "17402204"}}
{"text": "However, more and smaller fibroadenomas were detected in the instruction group than in the control group (P< 0.01).", "user_data": {"pmid": "17402204"}}
{"text": "Both arms exhibited minimal toxicity (grade 3/4 neutropenia <20%, leukopenia <9%, and other toxicities <5%).", "user_data": {"pmid": "17575230"}}
{"text": "Tumor samples from 49 patients were assessed for the expression levels of 12 pemetrexed-related genes.", "user_data": {"pmid": "17575230"}}
{"text": "Folylpolyglutamate synthetase and thymidine phosphorylase correlated with efficacy.", "user_data": {"pmid": "17575230"}}
{"text": "Best response rates and median time to tumor progression for high versus low thymidine phosphorylase expression were 27.6% versus 6.3% (P = 0.023) and 5.4 versus 1.9 months (P = 0.076), and for folylpolyglutamate synthetase were 37.5% versus 10.0% (P = 0.115) and 8.6 versus 3.0 months (P = 0.019), respectively.", "user_data": {"pmid": "17575230"}}
{"text": "gamma-Glutamyl hydrolase expression correlated with grade 3/4 toxicities: 78.6% for high versus 27.3% for low gamma-glutamyl hydrolase (P = 0.024).", "user_data": {"pmid": "17575230"}}
{"text": "Of 1857 patients, 79 (4.3%) developed a syndrome of bowel wall injury (BWI, small or large) characterized by hospitalization for the management of severe diarrhea or dehydration and radiographic or endoscopic evidence of bowel wall thickening or ulceration.", "user_data": {"pmid": "17853393"}}
{"text": "Severe gastrointestinal toxicity usually occurred during the third or fourth week on the first cycle of therapy, required hospitalization, and was managed with fluids, antidiarrheals, and antibiotics.", "user_data": {"pmid": "17853393"}}
{"text": "Compliance was excellent, with 7,286 questionnaires analyzed.", "user_data": {"pmid": "17947724"}}
{"text": "Baseline symptom prevalence ranged from 2% (vaginal bleeding) to 60% to 70% (bone/muscle aches and low energy).", "user_data": {"pmid": "17947724"}}
{"text": "There were no significant differences in vaginal bleeding, mood alteration, or low energy.", "user_data": {"pmid": "17947724"}}
{"text": "Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001).", "user_data": {"pmid": "17947724"}}
{"text": "Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03).", "user_data": {"pmid": "17947724"}}
{"text": "In both groups, the hot flash score peaked at 3 months and decreased thereafter.", "user_data": {"pmid": "17947724"}}
{"text": "In the current analysis, there was no evidence of interaction, and we were able to examine each intervention separately.", "user_data": {"pmid": "18235123"}}
{"text": "The chemotherapy regimens resulted in similar EFS and overall survival.", "user_data": {"pmid": "18235123"}}
{"text": "There was a trend toward better EFS with the addition of MTP (P = .08).", "user_data": {"pmid": "18235123"}}
{"text": "The hazard ratio for overall survival with the addition of MTP was 0.71 (95% CI, 0.52 to 0.96).", "user_data": {"pmid": "18235123"}}
{"text": "No statistically significant differences were demonstrated in terms of median overall survival and time to disease progression.", "user_data": {"pmid": "19729979"}}
{"text": "These effects were greater in women age 60 to 79 years (P = .03 for interaction across age).", "user_data": {"pmid": "19901118"}}
{"text": "Baseline mean scores and rates at which pts failed to complete QoL assessment were similar in the two arms.", "user_data": {"pmid": "19910076"}}
{"text": "Global health status of the EORTC QLQ-C30 scale and specific symptoms control (LC13 module) improved during treatment without any statistically significant difference between the two arms.", "user_data": {"pmid": "19910076"}}
{"text": "Emotional functioning remained stable in both groups during treatment, whereas physical and role improved slightly.", "user_data": {"pmid": "19910076"}}
{"text": "In the DCT/CDDP arm 14 pts (33%; 95%CL 24-40%) had PR, and 10 (24%) SD for a 57% TGCR.", "user_data": {"pmid": "19910076"}}
{"text": "In the VNR/CDDP arm 12 pts (27%) achieved PR, 18 (41%) SD a 68% TGCR.", "user_data": {"pmid": "19910076"}}
{"text": "Differences were not statistically significant.", "user_data": {"pmid": "19910076"}}
{"text": "Febrile neutropenia rate was higher in the VNR/CDDP arm (p=0.02) as well as G3-4 anemia (p=0.005) and G-CSF/EPO use (p=0.019).", "user_data": {"pmid": "19910076"}}
{"text": "Grade 3/4 non-haematologic toxicity was infrequent in both arms.", "user_data": {"pmid": "20089562"}}
{"text": "Congestive heart failure was observed in one patient in each arm.", "user_data": {"pmid": "20089562"}}
{"text": "A total of 80 patients were entered in this trial.", "user_data": {"pmid": "20147856"}}
{"text": "The primary end point of this study was response rate.", "user_data": {"pmid": "20147856"}}
{"text": "Median time to treatment failure in arm A was 3.6 months and 4.8 months in arm B. Median time to progression in arm A was 4.1 months and 5.5 months in arm B. Median survival time in arm A and arm B was 15.5 months and 18.8 months, respectively.", "user_data": {"pmid": "20147856"}}
{"text": "The toxicity profile was relatively mild and did not differ very much between two arms.", "user_data": {"pmid": "20147856"}}
{"text": "The DA was helpful, balanced and clear, and did not make women anxious.", "user_data": {"pmid": "20149953"}}
{"text": "In this cohort, quantitative image analysis showed significantly larger biopsies regarding size and artifact-free tissue sections for cryobiopsy compared with forceps biopsy (P < .0001).", "user_data": {"pmid": "20226474"}}
{"text": "The overall diagnostic yield of cryobiopsy was 89.5%.", "user_data": {"pmid": "20226474"}}
{"text": "Mild bleeding occurred in 11 cases (3.7%), moderate bleeding occurred in 3 cases (1.0%), and severe bleeding occurred in 1 case (0.3%).", "user_data": {"pmid": "20226474"}}
{"text": "Demographic and clinical profiles of both groups were not statistically different.", "user_data": {"pmid": "20506785"}}
{"text": "Logistic regression analyses showed that no having creation a pleural tent procedure was the most significant predictive factor of the occurrence and duration of prolonged air leaks.", "user_data": {"pmid": "20506785"}}
{"text": "A greater reduction in the duration of air leaks was observed before postoperative day 4 in group 1, and logistic regression analysis showed that having a pleural tent procedure was the most significant predictive factor of air leaks that persisted for less than 4 days.", "user_data": {"pmid": "20506785"}}
{"text": "Medastinal N3 disease was the risk factor for INF (P = 0.02, OR = 14.13, 95% CI: 1.47-136.13).", "user_data": {"pmid": "20673485"}}
{"text": "During radiotherapy, grade I, II weight loss was observed in 29.4%, 5.9% and 56.4%, 7.7% patients respectively (P = 0.04).", "user_data": {"pmid": "20673485"}}
{"text": "Grade 0-I and II-III late pulmonary injury was developed in 97.1%, 2.9% and 86.4%, 15.4% patients respectively (P = 0.07).", "user_data": {"pmid": "20673485"}}
{"text": "Median survival time was 22.1 months and 26.9 months respectively.", "user_data": {"pmid": "20673485"}}
{"text": "The 1 to 3-year OS were 77.9%, 44.4%, 37.3% and 75.8%, 56.3%, 41.7% respectively (P = 0.79).", "user_data": {"pmid": "20673485"}}
{"text": "There were no significant differences between treatment groups for mean change in Fridericia's correction of QT during the trial.", "user_data": {"pmid": "20952020"}}
{"text": "Other arrhythmias occurred in 1% or less of subjects by treatment group.", "user_data": {"pmid": "20952020"}}
{"text": "Cox proportional hazard ratio estimates for selected baseline covariates showed a significantly increased risk of cardiovascular events by age (p=0.0459) and systolic blood pressure (p=0.0061).", "user_data": {"pmid": "20952020"}}
{"text": "Denosumab was superior to zoledronic acid in delaying time to first on-study SRE (hazard ratio, 0.82; 95% CI, 0.71 to 0.95; P = .01 superiority) and time to first and subsequent (multiple) on-study SREs (rate ratio, 0.77; 95% CI, 0.66 to 0.89; P = .001).", "user_data": {"pmid": "21060033"}}
{"text": "Reduction in bone turnover markers was greater with denosumab.", "user_data": {"pmid": "21060033"}}
{"text": "Overall survival, disease progression, and rates of adverse events (AEs) and serious AEs were similar between groups.", "user_data": {"pmid": "21060033"}}
{"text": "An excess of renal AEs and acute-phase reactions occurred with zoledronic acid; hypocalcemia occurred more frequently with denosumab.", "user_data": {"pmid": "21060033"}}
{"text": "Despite over-accrual of 475 patients, the trial matured with only 324 of 385 planned TtP events due to patient discontinuations.", "user_data": {"pmid": "21084429"}}
{"text": "Human epidermal growth factor receptor 2 status was not captured in this study.", "user_data": {"pmid": "21084429"}}
{"text": "TtP [hazard ratio (HR) = 1.101, 95% confidence interval (CI) 0.885-1.370, P = 0.387] and OS (HR = 1.031, 95% CI 0.830-1.280, P = 0.785) were not significantly different comparing GD and CD.", "user_data": {"pmid": "21084429"}}
{"text": "TtP, OS, and ORR were not significantly different comparing crossover groups.", "user_data": {"pmid": "21084429"}}
{"text": "GD caused greater fatigue, hepatotoxicity, neutropenia, and thrombocytopenia but not febrile neutropenia; CD caused more hand-foot syndrome, gastrointestinal toxicity, and mucositis.", "user_data": {"pmid": "21084429"}}
{"text": "In stratum 1 (n = 206), the PFS HR (gefitinib:placebo) was 0.84 (95% CI, 0.59-1.18; median PFS 10.9 versus 8.8 months).", "user_data": {"pmid": "21220480"}}
{"text": "In the stratum 1 endocrine therapy-na\u00efve subset (n = 158) the HR was 0.78 (95% CI, 0.52-1.15), and the prior endocrine-treated subgroup (n = 48) 1.47 (95% CI, 0.63-3.45).", "user_data": {"pmid": "21220480"}}
{"text": "In stratum 1, CBRs were 50.5% with gefitinib and 45.5% with placebo.", "user_data": {"pmid": "21220480"}}
{"text": "Biomarker analysis suggested that in stratum 1 there was greater benefit with gefitinib in patients who were ER-negative or had lower levels of ER protein.", "user_data": {"pmid": "21220480"}}
{"text": "This difference in the pattern of recurrence was of borderline statistical significance (P = 0.07).", "user_data": {"pmid": "8614420"}}
{"text": "There was no significant difference in survival whether treatment was administered to the prostate or prostate and pelvic lymph nodes.", "user_data": {"pmid": "9531360"}}
{"text": "In the 1202 men studied, 361 cases of prostate cancer were diagnosed.", "user_data": {"pmid": "9697788"}}
{"text": "Both PSA-D and PSA-T showed a significantly higher area under the ROC curve (0.77 and 0.79, respectively) than PSA alone (area 0.65).", "user_data": {"pmid": "9697788"}}
{"text": "There was no significant difference between PSA-D and PSA-T. ", "user_data": {"pmid": "9697788"}}
{"text": "The use of a PSA-D threshold value of 0.10 ng/mL/cc would have avoided 28% of biopsies at the cost of 10% of detectable cancers.", "user_data": {"pmid": "9697788"}}
{"text": "A PSA-D threshold of 0.15 ng/mL/cc would have avoided 73.8% of biopsies at the cost of not diagnosing 43.8% of detectable cancers.", "user_data": {"pmid": "9697788"}}
{"text": "Lymphocysts appeared in 23/61 patients (38%) in total.", "user_data": {"pmid": "9701205"}}
{"text": "No patients in the \"no-closure\" group required surgical procedures such as needle aspiration or cyst drainage.", "user_data": {"pmid": "9701205"}}
